University Hospitals of North Midlands NHS Trust   Report issue

Academic/Hospital Phase 3 Phase 4
Founded: Stoke-on-Trent United Kingdom (2014)

Organization Overview

First Clinical Trial
2014
NCT01526161
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Professor Warren Lenney | University Hospitals of North Midlands NHS Trust | University Hospitals of North Midlands NHS Trust, Royal Stoke University Hospital, Oncology Department, City General Site, Newcastle Road, Stoke on Trent, ST4 6QG

Active Ingredients

Drugs in Phase 4 Trials (4)

atorvastatin (lipitor) (1 trial)

fluticasone (cutivate) (1 trial)

montelukast (singulair) (1 trial)

salmeterol (serevent) (1 trial)

Drugs in Phase 3 Trials (1)

ondansetron (zofran) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Coronary Syndrome (Phase 4)

Asthma (Phase 4)

Diarrhea (Phase 3)

Irritable Bowel Syndrome (Phase 3)

Syndrome (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 3
  • # of Trial APIs: 5